For the studies that reported the immunohistochemistry status in our review, most of the cases in our review were hormone receptor-positive (either estrogen receptor [ER] or progesterone receptor [PR] or both) and Her-2 receptor negative; this should expectedly, as shown by some studies [26-28], mean a less aggressive tumor type, reduced recurrence including effusion and a relatively good prognosis. This evidence concerns the gene ESR1 and neoplasm.